Loading...
OTCM
BPTH
Market cap714kUSD
Dec 05, Last price  
0.09USD
1D
17.81%
1Q
-28.33%
Jan 2017
-100.00%
IPO
-100.00%
Name

Bio Path Holdings Inc

Chart & Performance

D1W1MN
OTCM:BPTH chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
78.40%
Rev. gr., 5y
100.00%
Revenues
0k
59,45343,81218,4380000000013,00037,0000000000
Net income
-10m
L-38.46%
-84,538-147,909-52,546-2,852,767-1,969,738-2,081,500-2,363,344-2,582,537-3,266,013-4,519,949-5,466,794-6,750,000-7,023,000-8,583,000-8,505,000-10,856,000-10,437,000-13,835,000-16,078,000-9,894,000
CFO
-11m
L-8.32%
-54,964-101,756-64,913-930,600-1,567,446-1,148,156-1,149,911-1,993,404-2,313,160-3,817,497-5,004,291-8,148,000-7,957,000-6,124,000-8,361,000-10,960,000-9,917,000-15,103,000-11,535,000-10,575,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
URL
https://www.biopathholdings.com/
IPO date
Jan 11, 2006
Employees
10
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT